Identification of prognostic immune-related genes and evaluation of chemotherapy and immunotherapy responses in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense extracellular matrix and a complex tumor microenvironment, which contribute to poor prognosis and limited response to anti-tumor therapies. Although immunotherapy has emerged as a promising strategy, only a subset of patients derives clinical benefit. Therefore, identifying reliable biomarkers to predict prognosis and therapeutic response remains an urgent need. This study aims to systematically screen and evaluate key immune-related genes associated with the prognosis and immunotherapeutic response of PDAC, in order to identify reliable biomarkers and provide potential targets for personalized treatment.